rethinkTHC Search
Menu
Study breakdown

Pure CBD and THC Formulations Showed Moderate Benefits for Anxiety and PTSD in Meta-Analysis of 21 Trials

Meta AnalysisModerate evidence
The takeaway

A meta-analysis of 21 RCTs found pharmaceutical-grade CBD and THC showed moderate effects for anxiety disorders and PTSD, though evidence remains limited by small samples and heterogeneous designs.

Psychiatrists considering cannabinoid treatments, medical cannabis researchers, patients seeking evidence on cannabis for anxiety.

Pure CBD: moderate effect (SMD -0.61)

What the researchers found

Across 21 placebo-controlled RCTs covering social anxiety, GAD, PTSD, OCD, and Tourette syndrome, pure CBD compounds showed a moderate significant effect (SMD -0.61, 95% CI -1.15 to -0.07). THC-dominant compounds also showed moderate significance (SMD -0.65, 95% CI -1.06 to -0.24). However, CBD-THC mixtures did not reach significance (SMD -0.73, 95% CI -2.00 to 0.55). Pharmaceutical-grade formulations appeared to outperform non-standardized extracts.

Why it matters

This is one of the most comprehensive meta-analyses to date separating cannabinoid types across anxiety-related conditions. The finding that pharmaceutical-grade formulations outperform non-standardized extracts has direct implications for both clinical practice and regulation of medical cannabis for mental health conditions.

The numbers in context

21 RCTs included. Pure CBD: SMD -0.61 (significant). THC-dominant: SMD -0.65 (significant). CBD-THC mixtures: SMD -0.73 (not significant). Conditions: SAD (5 trials), GAD (1), PTSD (7), OCD (1), Tourette (7).

How the study worked

Systematic review and meta-analysis searching PubMed, Embase, PsycInfo, Web of Science, Scielo, and Lilacs for placebo-controlled RCTs. 21 trials included: 5 for social anxiety, 1 GAD, 7 PTSD, 1 OCD, 7 Tourette syndrome. Separate meta-analyses by cannabinoid subtype. Standardized mean differences calculated using Jamovi software.

What this study cannot tell us

Small sample sizes across most included trials. Heterogeneous study designs, doses, and outcome measures. Some conditions had very few trials (1 each for GAD and OCD). Cannot compare conditions head-to-head. THC results driven partly by Tourette syndrome trials which may involve different mechanisms than anxiety.

How to read the evidence

Moderate: rigorous meta-analytic methodology across 21 RCTs, though limited by small trials, heterogeneous designs, and few studies per condition.

When this study was published

2025 study

The bigger picture

The superiority of pure formulations over mixtures challenges the popular "entourage effect" hypothesis for mental health conditions. It suggests that for anxiety and PTSD, precise dosing of specific cannabinoids may matter more than whole-plant approaches, aligning with pharmaceutical rather than dispensary models of care.

Questions still open

  • Why do CBD-THC mixtures perform worse than pure compounds for anxiety? Would larger, better-designed trials confirm the moderate effects seen here? Should medical cannabis regulations require pharmaceutical-grade formulations for mental health indications?

Common questions

Does cannabis help with anxiety?
This meta-analysis found pharmaceutical-grade CBD and THC showed moderate benefits across anxiety-related conditions, but evidence is still limited. Importantly, CBD-THC mixtures did not show significant benefits, suggesting pure formulations may work better.
Is CBD or THC better for anxiety disorders?
Both pure CBD and THC-dominant formulations showed similar moderate effect sizes. CBD was studied more for social anxiety and GAD, while THC was studied more for PTSD nightmares and Tourette syndrome. The conditions may respond to different cannabinoids.

Read the original research

Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.

Cannabis and cannabinoid research, 10(6), 655-672

Citation

Raminelli, Adrieli Oliveira; Simei, João Luís Q; Guimarães, Francisco S; Zuardi, Antônio; Hallak, Jaime Eduardo C; Crippa, José Alexandre; Osório, Flávia de Lima. (2025). Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.. Cannabis and cannabinoid research, 10(6), 655-672. https://doi.org/10.1177/25785125251378242

Explore the wider topic